Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

fludarabine 7Cyclophosphamide 6fludarabine phosphate 5Melphalan 4thymoglobulin 3Tacrolimus 3Methotrexate 3Cytarabine 3Busulfan 3trametinib 2blinatumomab 2Whole-Body Irradiation 2Transplantation 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Mesna 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Biopsy 2Azacitidine 2omipalisib 1merphos 1imetelstat 1hydrocortisone hemisuccinate 1Vorinostat 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × hydrocortisone hemisuccinate × 1 year × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡